{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:21:59Z","timestamp":1784042519456,"version":"3.55.0"},"reference-count":35,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate the validity of enthesitis indices in patients with peripheral spondyloarthritis (pSpA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>The ABILITY-2 study evaluated the efficacy of adalimumab (ADA) versus placebo (PBO) in patients with active pSpA over 12 weeks. Patients received open-label ADA for an additional 144 weeks. Twenty-nine enthesitis sites used in 3 enthesitis scoring systems [Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index, Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)] were assessed; discriminatory capacity and treatment response at Week 12 were calculated by standardized mean difference (SMD) and Guyatt\u2019s effect size (ES). Sites showing resolution or new-onset enthesitis from baseline to Week 12 were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Overall, 165 patients (ADA, n = 84; PBO, n = 81) were randomized; 143 had \u2265 1 enthesitis site at baseline. The LEI (SMD \u22120.73, ES \u22121.07) and SPARCC (SMD \u22120.56, ES \u22120.99) enthesitis indices showed higher discriminatory ability and treatment response than MASES (SMD \u22120.32, ES \u22120.81). At Week 12, among sites that were positive at baseline, significantly more (p &lt; 0.05) showed resolution among patients treated with ADA versus PBO in the Achilles tendon (60.4% and 36.5%, respectively), medial epicondyle (73.2%, 48.7%), lateral epicondyle (80.6%, 52.8%), and iliac crest (73.5%, 47.2%). Among negative sites at baseline, significantly less (p &lt; 0.05) new-onset enthesitis was observed with ADA versus PBO for Achilles tendon (3.6% and 10.9%, respectively), greater trochanter (3.4%, 14.4%), lateral epicondyle humerus (4.7%, 15.1%), medial femoral condyle (1.6%, 9.2%), and quadriceps insertion superior patella (1.5%, 7.0%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>The LEI and SPARCC enthesitis indices showed better discriminatory capacity and treatment response in patients with pSpA versus MASES, likely because these indices contain more peripheral sites. Trial registration number: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"ClinicalTrials.gov\" ext-link-type=\"uri\" xlink:type=\"simple\">ClinicalTrials.gov<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01064856\">NCT01064856<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.160387","type":"journal-article","created":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:10:44Z","timestamp":1489623044000},"page":"599-608","source":"Crossref","is-referenced-by-count":49,"title":["Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab"],"prefix":"10.3899","volume":"44","author":[{"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Sieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen L.","family":"Pangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Ho","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"2018112909365931000_44.5.599.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"2018112909365931000_44.5.599.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60071-8"},{"key":"2018112909365931000_44.5.599.3","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817"},{"key":"2018112909365931000_44.5.599.4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2854"},{"key":"2018112909365931000_44.5.599.5","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4419-0298-6_4"},{"key":"2018112909365931000_44.5.599.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"2018112909365931000_44.5.599.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.12.1167"},{"key":"2018112909365931000_44.5.599.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes251"},{"key":"2018112909365931000_44.5.599.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"2018112909365931000_44.5.599.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08215-6"},{"key":"2018112909365931000_44.5.599.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.23568"},{"key":"2018112909365931000_44.5.599.12","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.084244"},{"key":"2018112909365931000_44.5.599.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.2.127"},{"key":"2018112909365931000_44.5.599.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391209"},{"key":"2018112909365931000_44.5.599.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012664"},{"key":"2018112909365931000_44.5.599.16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20577"},{"issue":"Suppl 93","key":"2018112909365931000_44.5.599.17","first-page":"S44","article-title":"Assessment of disease activity in psoriatic arthritis","volume":"33","author":"Helliwell","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 11","key":"2018112909365931000_44.5.599.18","first-page":"S239","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (52-week) improvement in measures of disease activity in patients with psoriatic arthritis: results from 3 phase 3, randomized, controlled trials","volume":"66","author":"Kavanaugh","year":"2014","journal-title":"Arthritis Rheum"},{"key":"2018112909365931000_44.5.599.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"issue":"Suppl 11","key":"2018112909365931000_44.5.599.20","first-page":"S423","article-title":"A phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to evaluate the efficacy and safety of clazakizumab, an anti-IL-6 monoclonal antibody, in adults with active psoriatic arthritis","volume":"66","author":"Mease","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2018112909365931000_44.5.599.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2018112909365931000_44.5.599.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315231"},{"issue":"Suppl 2","key":"2018112909365931000_44.5.599.23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2015-eular.2276","article-title":"THU0421 Secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study (Future 2)","volume":"74","author":"Kirkham","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2018112909365931000_44.5.599.24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.39008","article-title":"Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis","volume":"67","author":"Mease","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2018112909365931000_44.5.599.25","unstructured":"Cohen J . Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale: Lawrence Erlbaum Associates; 1988."},{"key":"2018112909365931000_44.5.599.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094870"},{"key":"2018112909365931000_44.5.599.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204239"},{"key":"2018112909365931000_44.5.599.28","first-page":"1740","article-title":"International spondyloarthritis interobserver reliability exercise\u2014the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909365931000_44.5.599.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201217"},{"key":"2018112909365931000_44.5.599.30","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/acr.22191","article-title":"Defining enthesitis in spondyloarthritis by ultrasound: results of a Delphi process and of a reliability reading exercise","volume":"66","author":"Terslev","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2018112909365931000_44.5.599.31","first-page":"969","article-title":"Ultrasonographic evaluation of entheses in patients with spondyloarthritis: a systematic literature review","volume":"32","author":"Sakellariou","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909365931000_44.5.599.32","doi-asserted-by":"publisher","DOI":"10.1186\/ar3551"},{"key":"2018112909365931000_44.5.599.33","first-page":"933","article-title":"Comparison of ultrasonography and magnetic resonance imaging for the assessment of clinically defined knee enthesitis in spondyloarthritis","volume":"31","author":"Aydin","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909365931000_44.5.599.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139667"},{"key":"2018112909365931000_44.5.599.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200336"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.160387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T19:15:55Z","timestamp":1543518955000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.160387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,1]]},"published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.3899\/jrheum.160387"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.160387","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]}}}